EMERGENCY:Rapidly worsening weakness reaching arms and breathing muscles in a known CIDP patient — this is a CIDP relapse emergency. —call040-46324365immediately — 24 hours, 7 days— 24/7
CIDP — Chronic Inflammatory Demyelinating Polyneuropathy in Hyderabad: Progressive Leg Weakness That Is Not Diabetic Neuropathy — And That Can Be Treated
Expert CIDP diagnosis with nerve conduction studies and long-term IVIG, corticosteroid, or plasmapheresis management at KIMS Neuroscience, Secunderabad, Hyderabad.
About This Condition
The Condition Behind the Slowly Failing Legs
A 52-year-old man in Hyderabad has been having progressive difficulty climbing stairs for the past four months. His legs feel heavy and his grip on the handrail has weakened. He has tingling in his hands and feet. His GP attributed it to his diabetes — he has had Type 2 diabetes for eight years. He was advised to tighten his blood sugar control. The tingling has not improved. The weakness is getting worse.
He comes to KIMS Neuroscience. Nerve conduction studies reveal slowed conduction velocity across multiple peripheral nerves — in both legs and both arms — with evidence of demyelination. His diabetic glucose control is actually reasonable. The pattern on NCS is not the length-dependent axonal neuropathy of diabetic peripheral neuropathy. It is diffuse, demyelinating, affecting proximal segments as well as distal — the electrodiagnostic signature of CIDP.
The most frequently reported conditions forming a misdiagnosis for CIDP were GBS followed by diabetic polyneuropathy at 28.7% and 14.2% respectively.
In India — where diabetes affects over 100 million people and diabetic peripheral neuropathy is extremely common — the CIDP misdiagnosis as diabetic neuropathy is one of the most consequential diagnostic errors in peripheral neurology. The patient with diabetic neuropathy receives supportive care; the patient with CIDP who is correctly diagnosed receives immunotherapy and — in most cases — improves significantly.
The difference between these two diagnoses is not made by blood sugar levels or HbA1c. It is made by nerve conduction studies interpreted by a neurologist who recognises the CIDP electrodiagnostic pattern — available at KIMS Neuroscience, Secunderabad.
Book a Consultation
Speak directly with our peripheral neuropathy specialist team. No referral required. Monday to Saturday.
040-44885000Emergency line: 040-46324365CIDP at a Glance
The clinical and epidemiological essentials of CIDP — including the diagnostic threshold, the most common misdiagnoses, and the risk of delay.
What it is
A chronic autoimmune attack on peripheral nerve myelin — producing progressive limb weakness, numbness, and absent reflexes over 8 weeks or more; essentially the chronic, relapsing counterpart of GBS.
How common
Prevalence ranges between 0.67 and 10.3 per 100,000; incidence estimated at 0.15 to 1.6 per 100,000 per year; prevalence in India estimated at 1.1 per 100,000 — likely an underestimate given diagnostic challenges.
Who it affects
Mean age of onset around 40–60 years; men more frequently affected than women at a 2:1 ratio.
The diagnostic rule
Weakness progressing for more than 8 weeks — this is the single most important threshold that separates CIDP from GBS.
The most common misdiagnosis
The most frequently reported misdiagnosis for CIDP was GBS followed by diabetic polyneuropathy at 28.7% and 14.2% respectively — both common in India.
The good news
CIDP is treatable — IVIG, corticosteroids, and plasmapheresis all produce meaningful improvement; many patients achieve sustained remission.
The risk of delay
Untreated CIDP can result in axonal loss and permanent nerve damage — the window for full recovery narrows with every month of delayed diagnosis.
Appointment
040-44885000
What CIDP Is — The Chronic Peripheral Nerve Immune Attack
CIDP is an immune-mediated polyneuropathy marked by nerve root and peripheral nerve inflammation, characterised by segmental demyelination and remyelination. Typical CIDP presents with symmetric, motor-predominant weakness and sensory impairment, notably affecting vibration and position sense more than pain and temperature, often accompanied by areflexia.
In plain terms: CIDP is what happens when the immune system launches a slow, sustained, chronic attack on the myelin of the peripheral nerves — the nerves in the arms, legs, and nerve roots where the peripheral nervous system connects to the spinal cord. Unlike GBS, which is an acute attack that peaks within 4 weeks, CIDP progresses over months to years. Unlike diabetic neuropathy, which follows the length of the nerves (feet affected first and most severely), CIDP often affects proximal muscles — the thighs and shoulder girdle — as prominently as the feet.
The immune mechanism differs from MS and NMO. In CIDP, the target is peripheral nerve myelin and the paranodal proteins at the nodes of Ranvier — not central nervous system myelin. This means CIDP does not cause brain MRI abnormalities, does not cause cognitive problems, and does not respond to the disease-modifying therapies used in MS.
CIDP develops in 3 to 10% of people with GBS. A patient who was diagnosed with GBS, treated with IVIG or plasmapheresis, initially improved — and then deteriorated again months later — should be re-evaluated for CIDP at KIMS. This transition from GBS to CIDP is more common than most treating physicians expect.
CIDP vs. GBS — The Critical 8-Week Rule
The single most important clinical distinction between CIDP and GBS is the time course.
GBS
Weakness progresses to its maximum over 2–4 weeks, then plateaus and begins to recover. The total period of worsening is under 4 weeks in the vast majority of cases.
CIDP
Weakness progresses for more than 8 weeks — either continuously, or in a relapsing-remitting pattern. Although symptoms of CIDP resemble those of GBS, the two can be differentiated based on how long symptoms have continued to progress — more than 2 months for CIDP.
The overlap zone
Some patients present at 5–7 weeks of progressive weakness — between the GBS and CIDP time frames. These patients are classified as "subacute inflammatory demyelinating polyneuropathy" and are treated as CIDP in practice. The 8-week threshold is a diagnostic criterion, not a biological cutoff.
The relapsing pattern in CIDP
Approximately one-third of CIDP patients follow a relapsing-remitting course — episodes of worsening, partially recovering, and worsening again. This pattern, in a patient with an established CIDP diagnosis, is a treatment decision trigger — not reassurance. Each relapse risks permanent axonal damage if untreated.
Symptoms — What CIDP Feels Like Over Months
CIDP develops over months. These are the most common presentations — described as a patient might describe them.
Progressive leg weakness
Difficulty rising from a low chair or toilet without arm support. Difficulty climbing stairs. Difficulty walking on uneven ground. The weakness often affects the proximal muscles — thighs, hip flexors, shoulder — as much as the distal muscles, which is the clinical clue that distinguishes CIDP from diabetic neuropathy (where proximal involvement is minimal).
Absent or reduced reflexes
Deep tendon reflexes — knee jerk, ankle jerk, biceps reflex — are reduced or completely absent in CIDP. This is one of the most consistent and detectable clinical signs, easily assessed at KIMS and in any GP clinic. A patient with progressive leg weakness and absent knee jerks does not have straightforward diabetic neuropathy — they need nerve conduction studies urgently.
Sensory symptoms — tingling, numbness, and balance problems
Tingling and numbness in hands and feet are common but often less prominent than the weakness. More diagnostically useful is loss of position sense — the patient cannot feel where their feet are in space without looking, leading to gait unsteadiness in the dark or on uneven surfaces. This proprioceptive loss reflects large myelinated fibre involvement — the specific fibre type targeted in CIDP demyelination.
Vibration loss
Loss of the ability to feel vibration from a tuning fork at the toes and ankles — a reliable bedside sign of large-fibre peripheral nerve damage, and easy to test at KIMS.
Pain
Neuropathic pain — burning, electrical, or aching discomfort in the feet and legs — is present in a substantial proportion of CIDP patients. In the Indian context, this pain is frequently attributed to musculoskeletal disease or diabetic neuropathy and treated symptomatically, while the underlying CIDP goes undiagnosed.
What is typically NOT present in CIDP (unlike GBS)
Severe autonomic instability, respiratory involvement, facial diplegia — the life-threatening features of GBS. In contrast to GBS, cranial nerves, respiratory muscles, and the autonomic nervous system are rarely affected in CIDP.
Diagnosis at KIMS
The India-Specific Diagnostic Problem — CIDP vs. Diabetic Neuropathy
India has the second largest diabetic population in the world — over 100 million people with Type 2 diabetes. Diabetic peripheral neuropathy affects approximately 50% of people with long-standing diabetes. In Hyderabad — one of India's major urban centres with high rates of sedentary lifestyle and refined carbohydrate consumption — diabetic neuropathy is among the most common peripheral nerve conditions seen by neurologists.
Patients from the Indian cohort in an Indo-European CIDP management study were the most severely affected with less diverse therapeutic approaches. This severity likely reflects delayed diagnosis — Indian CIDP patients present later in the disease course, with more accumulated nerve damage, because the CIDP diagnosis was not made when it should have been.
The problem
CIDP and diabetic neuropathy share several features — tingling, numbness, weak legs, reduced reflexes. The diagnosis of "diabetic neuropathy" is frequently applied on the basis of the presence of diabetes and peripheral symptoms, without nerve conduction studies that would show the demyelinating pattern of CIDP.
Diabetic neuropathy on NCS
Reduced amplitude (axon loss), length-dependent pattern (legs worse than arms, distal worse than proximal), normal or near-normal conduction velocity.
CIDP on NCS
Prolonged distal latencies and markedly slowed conduction velocity (demyelination), proximal slowing (nerve root involvement — shown by prolonged F-wave latency), conduction block — a drop in signal amplitude between proximal and distal stimulation of the same nerve. These are distinct and identifiable electrodiagnostic patterns. A patient with diabetes but CIDP-pattern NCS has CIDP — and needs immunotherapy, not tighter blood sugar control.
Diagnosis at KIMS
CIDP is diagnosed using the EAN/PNS 2021 criteria — the current international standard. The diagnosis combines NCS evidence of primary demyelination with clinical features (progressive or relapsing weakness over more than 8 weeks, sensory involvement, reduced or absent reflexes) and supportive investigations.
At KIMS, the NCS is not interpreted in isolation — it is assessed as part of a complete diagnostic evaluation that excludes hereditary demyelinating neuropathies (Charcot-Marie-Tooth disease), hypothyroid neuropathy, paraprotein-associated neuropathy, and other conditions that can produce slowed conduction.
Nerve Conduction Studies (NCS) and EMG — the essential investigation
Electrodiagnostic testing reveals evidence of primary demyelination. At KIMS, the full NCS protocol for suspected CIDP includes: motor and sensory conduction velocity in multiple nerves in both arms and legs, distal latency measurement, F-wave latency assessment (reflecting proximal nerve root conduction), and conduction block assessment. The EAN/PNS 2021 diagnostic criteria for CIDP require specific NCS findings — KIMS applies these criteria systematically.
Lumbar Puncture — CSF protein
CSF protein elevation — reflecting nerve root inflammation — is present in approximately 80% of CIDP patients. The specific finding is elevated protein with a normal white cell count (similar to GBS). This supports the diagnosis but is not required if NCS findings already meet diagnostic criteria.
MRI — nerve roots and plexus
MRI of the lumbosacral and cervical spine with gadolinium can show nerve root enhancement and thickening in CIDP — supporting the diagnosis and ruling out structural causes of peripheral neuropathy (disc compression, neoplastic infiltration). Nerve ultrasound is emerging as a useful additional tool showing nerve enlargement in CIDP.
Blood tests — excluding secondary causes
Paraprotein screen (serum protein electrophoresis and immunofixation) — to identify monoclonal gammopathy, which can cause CIDP-like demyelinating neuropathy. Glucose and HbA1c — to quantify the diabetic contribution. Thyroid function — hypothyroid neuropathy can mimic CIDP. Vitamin B12, folate. HIV, hepatitis B and C serology. ANA and other connective tissue disease markers — CIDP is associated with Sjögren's syndrome and SLE in a subset of cases.
Nodal/paranodal antibody panel
Approximately 10% of patients with CIDP exhibit autoantibodies against nodal and paranodal proteins — primarily IgG4 antibodies against neurofascin-155 and contactin-1. These antibodies identify a CIDP subtype called autoimmune nodopathy — which has distinct clinical features (often younger onset, prominent ataxia, poor response to IVIG) and is identified by specific antibody testing available at KIMS. This subtype is specifically mentioned because IVIG is often ineffective in NF155-antibody-positive nodopathy — distinguishing it from typical CIDP changes the treatment approach.
Treatment
Treatment at KIMS — IVIG, Corticosteroids, Plasmapheresis
Unlike GBS — where steroids do not help — all three first-line CIDP treatments (IVIG, corticosteroids, and plasmapheresis) have proven efficacy.
IVIG (Intravenous Immunoglobulin)
The most commonly used first-line treatment. IVIG is often offered first because it does not have the many adverse effects of long-term corticosteroid use and is easier to administer than plasma exchange. The induction dose is 2g/kg over 2–5 days, followed by maintenance doses (typically 1g/kg every 3–4 weeks, adjusted based on response). IVIG requires regular re-dosing — unlike corticosteroids, its effects are not sustained after stopping. The major barrier in India is cost — IVIG maintenance therapy is expensive. At KIMS, individual cost-benefit assessments are made, with plasmapheresis offered as a cost-effective alternative where ongoing IVIG is not feasible.
Corticosteroids
High-dose oral prednisolone or pulsed IV methylprednisolone or dexamethasone. Evidence suggests that pulsed corticosteroids may result in longer remissions and have a lower rate of serious adverse effects than IVIG. The practical advantage is cost — oral prednisolone is inexpensive and accessible in India. The disadvantage is the side-effect profile of long-term steroid use: weight gain, diabetes aggravation (particularly relevant in Indian CIDP patients who frequently have co-existing Type 2 diabetes), bone density loss, cataracts, and hypertension. At KIMS, bone protection (calcium, vitamin D, bisphosphonate) is prescribed concurrently with any prolonged steroid course, and blood sugar monitoring is intensified.
When CIDP is severe or IVIG is ineffective
If CIDP is severe or progresses rapidly, or if immune globulin is ineffective, plasma exchange may be used — people may need treatment for months or years. Plasmapheresis at KIMS is offered as:
Primary treatment for patients where IVIG is not feasible due to cost or contraindication
Second-line rescue for patients with inadequate IVIG response
Maintenance therapy (typically fortnightly exchanges) in patients with persistent disease requiring ongoing treatment
Steroid-sparing agents, rituximab, and SCIg
Azathioprine, mycophenolate mofetil, and cyclosporine — used as steroid-sparing agents for patients who respond to steroids but cannot tolerate long-term high doses; these take 3–6 months to demonstrate effect
Rituximab — the anti-CD20 B-cell therapy used in NMO and MS at KIMS — is used for refractory CIDP and for NF155-antibody-positive nodopathy, where it has shown specific efficacy
Subcutaneous immunoglobulin (SCIg) — an emerging maintenance option where patients self-administer weekly subcutaneous immunoglobulin doses at home, reducing the need for regular hospital attendance for IV infusions
Note on steroids: unlike GBS where steroids are contraindicated, steroids are appropriate in CIDP. A patient transferred with a GBS diagnosis who has been on steroids for 6 weeks and is still deteriorating may actually have CIDP — re-diagnosis is the priority.
Five-year follow-up evidence
A five-year follow-up study of 38 CIDP patients showed that 10 patients had complete remission with normal nerve conduction studies, and 23 had partial remission. Patients with a more favourable long-term prognosis had subacute onset, symmetrical presentation, good response to initial corticosteroid treatment, and nerve conduction abnormalities predominantly in distal nerve terminals.
The trajectory at KIMS
Most patients with CIDP who are diagnosed promptly and treated appropriately improve — often significantly. The return of strength and function is gradual — measured over months — but is real and meaningful. The priority is preventing the accumulation of axonal damage that occurs when CIDP goes untreated or undertreated, because axonal loss is less reversible than demyelination.
Prognosis and Long-Term Management
A five-year follow-up study of 38 CIDP patients showed that 10 patients had complete remission with normal nerve conduction studies, and 23 had partial remission. Patients with a more favourable long-term prognosis had subacute onset, symmetrical presentation, good response to initial corticosteroid treatment, and nerve conduction abnormalities predominantly in distal nerve terminals.
The trajectory at KIMS: most patients with CIDP who are diagnosed promptly and treated appropriately improve — often significantly. The return of strength and function is gradual — measured over months — but is real and meaningful. The priority is preventing the accumulation of axonal damage that occurs when CIDP goes untreated or undertreated, because axonal loss is less reversible than demyelination.
Long-term management at KIMS includes
3-monthly NCS to track treatment response and detect subclinical deterioration
Regular clinical disability assessment
Steroid side-effect monitoring — bone density, blood sugar, blood pressure, eye pressure
IgG level monitoring in patients on regular IVIG
Treatment tapering assessment — some patients achieve sustained remission and can gradually reduce or stop treatment; this process requires structured monitoring to detect early relapse
When Should You Seek an Urgent CIDP Assessment?
Come to KIMS Neuroscience, Hyderabad urgently if you notice any of the following. Untreated CIDP can result in axonal loss and permanent nerve damage — the window for full recovery narrows with every month of delayed diagnosis.
Every patient presenting with progressive limb weakness over 8 weeks or more undergoes full electrodiagnostic assessment at KIMS — nerve conduction studies, F-wave latency, conduction block analysis — to distinguish CIDP from diabetic neuropathy, hereditary neuropathy, and other causes.
Progressive limb weakness over 8 weeks or more — particularly difficulty climbing stairs, rising from a chair, or grip weakness
Weakness that affects the thighs and hip flexors as prominently as the feet — proximal involvement is a CIDP signal
Tingling and numbness in a diabetic patient whose weakness is disproportionate to the typical diabetic neuropathy pattern
Absent or markedly reduced knee jerks alongside progressive weakness
A previous GBS diagnosis with partial recovery, then renewed deterioration weeks or months later
Loss of position sense — gait unsteadiness in the dark or on uneven surfaces
Rapidly worsening weakness reaching arms and breathing muscles in a known CIDP patient — this is a CIDP relapse emergency. Call 040-46324365 immediately — 24 hours, 7 days.
Related Conditions
CIDP belongs to the family of demyelinating and inflammatory disorders affecting the peripheral and central nervous systems:
FAQs
Frequently Asked Questions
Weakness that gets worse over months, absent knee jerks, and tingling in a diabetic patient — this is not necessarily just diabetic neuropathy. A nerve conduction study will tell the difference.
At KIMS Neuroscience, Secunderabad, Hyderabad, every patient presenting with progressive limb weakness over 8 weeks or more undergoes full electrodiagnostic assessment — nerve conduction studies, F-wave latency, conduction block analysis — to distinguish CIDP from diabetic neuropathy, hereditary neuropathy, and other causes. If CIDP is confirmed, a personalised treatment plan is built around IVIG, corticosteroids, plasmapheresis, or subcutaneous immunoglobulin — individually selected for efficacy, tolerability, and cost. Because untreated CIDP causes permanent nerve damage. Treated CIDP, in most patients, improves.
International enquiries: info@kimsneurosciences.com